Introduction
The insulin-like growth factors — IGF-1 and IGF-2 — are closely related peptide hormones that play central roles in cell growth, development, and metabolism throughout the body. While they share structural similarities and some receptor overlap, they have distinct physiological roles, receptor preferences, and research applications. This guide compares IGF-1 and IGF-2 for researchers working in this important growth factor axis.
Structure and Similarity
IGF-1 and IGF-2 are both single-chain polypeptides with structural homology to proinsulin. IGF-1 consists of 70 amino acids while IGF-2 has 67 amino acids. They share approximately 67% amino acid sequence identity and adopt similar three-dimensional structures. Both contain A, B, C, and D domains analogous to proinsulin, reflecting their evolutionary relationship to insulin.
Receptor Binding Profiles
IGF-1 binds preferentially to the IGF-1 receptor (IGF-1R), a tyrosine kinase receptor that mediates the primary anabolic and growth-promoting effects of the IGF axis. IGF-2 binds both IGF-1R and the IGF-2 receptor (IGF-2R, also called the cation-independent mannose 6-phosphate receptor). The IGF-2R acts primarily as a clearance receptor, internalizing and degrading IGF-2 without transmitting classical growth signaling. Both peptides can also bind insulin receptors with lower affinity than insulin.
Physiological Roles
IGF-1 is the primary mediator of the anabolic effects of growth hormone — GH stimulates hepatic IGF-1 production, which then acts systemically to promote muscle protein synthesis, bone growth, and metabolic regulation. Its levels decline significantly with age, and this decline is linked to sarcopenia and metabolic aging. IGF-2 is particularly important during fetal development and early postnatal growth, with relatively higher expression prenatally that decreases after birth in humans. In adults, IGF-2 maintains roles in glucose metabolism and tissue maintenance.
Cancer Research Relevance
Both IGF-1 and IGF-2 have significant relevance to cancer research. IGF-1R is overexpressed in many tumor types and has been studied as a therapeutic target. IGF-2 overexpression through genomic imprinting disruption has been identified in multiple cancers including Wilms tumor, colorectal cancer, and breast cancer. The IGF axis represents one of the most studied growth factor systems in oncology research.
Research Tools: IGF-1 LR3 and IGF-2
IGF-1 LR3 is the most commonly used research form of IGF-1, modified to reduce IGFBP binding and extend half-life. For IGF-2 research, both native IGF-2 and long-R3 IGF-2 analogues are used. IGF-1 LR3 is substantially more common in preclinical research than IGF-2 analogues, reflecting the greater research focus on IGF-1 axis effects in muscle biology, metabolism, and aging.
Conclusion
IGF-1 and IGF-2 are related but functionally distinct growth factors with different receptor preferences, developmental roles, and research applications. IGF-1 dominates adult GH axis research and muscle biology studies while IGF-2 has particularly importance in developmental biology and cancer research. Researchers should select the appropriate ligand based on the receptor subtype and biological pathway relevant to their study.